SCHEMBL31085256

SCHEMBL31085256

CCC1(C)Oc2ccc(C(C)=O)cc2O1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
CTNNB1 P35222 2/20 0.40
WNT3A P56704 2/20 0.40
ATM Q13315 1/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PKM P14618 1/20 0.38
AKR1B1 P15121 1/20 0.37
CREBBP Q92793 1/20 0.37
POLB P06746 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
APEX1 P27695 1/20 0.37
RECQL P46063 1/20 0.37
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 2/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11586028 0.87 ALDH1A1 (0.46) KDM4ECTNNB1WNT3AATMALDH1A1
SCHEMBL17567325 0.82 KDM4E (0.50) KDM4ECTNNB1WNT3APKMAKR1B1
SCHEMBL7153475 0.82 KDM4E (0.50) KDM4ECTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL11001655 0.78 LMNA (0.44) KDM4EALDH1A1SMN1; SMN2PKMPOLB
SCHEMBL1907961 0.77 KDM4E (0.49) KDM4ECTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL31085181 0.77 KDM4E (0.49) KDM4ECTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL1347343 0.77 CTNNB1 (0.58) KDM4ECTNNB1WNT3ASMN1; SMN2NPC1
SCHEMBL25745514 0.77 KDM4E (0.49) KDM4ECTNNB1WNT3AALDH1A1PKM
SCHEMBL11588847 0.76 HPGD (0.60) ALDH1A1POLBHPGDKMT2ATSHR
SCHEMBL6040443 0.75 ALPG (0.42) KDM4ECTNNB1WNT3AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 US disclosed
WO-2024160277-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2024-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 KDM4E 1832/4885CTNNB1 401/4885WNT3A 1771/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 KDM4E 2752/4885CTNNB1 410/4885WNT3A 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.